Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Genitourinary Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global genitourinary drugs market is expected to grow at a CAGR of around 4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:

The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on indication and product.

Breakup by Indication:

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence and Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Hematuria
  • Benign Prostatic Hyperplasia
     

Breakup by Product:

  • Urological
  • Hormonal Therapy
  • Gynecological
  • Anti-infectives
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Report Coverage:

Report Features Details
Base Year of the Analysis 2020
    Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Indication, Product, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global genitourinary drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global genitourinary drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the product?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global genitourinary drugs market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Genitourinary Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Indication
    6.1    Prostate Cancer
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Ovarian Cancer
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Bladder Cancer
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Cervical Cancer
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Renal Cancer
        6.5.1 Market Trends
        6.5.2 Market Forecast
    6.6    Erectile Dysfunction
        6.6.1 Market Trends
        6.6.2 Market Forecast
    6.7    Urinary Tract Infections
        6.7.1 Market Trends
        6.7.2 Market Forecast
    6.8    Urinary Incontinence and Overactive Bladder
        6.8.1 Market Trends
        6.8.2 Market Forecast
    6.9    Sexually Transmitted Diseases
        6.9.1 Market Trends
        6.9.2 Market Forecast
    6.10    Interstitial Cystitis
        6.10.1 Market Trends
        6.10.2 Market Forecast
    6.11    Hematuria
        6.11.1 Market Trends
        6.11.2 Market Forecast
    6.12    Benign Prostatic Hyperplasia
        6.12.1 Market Trends
        6.12.2 Market Forecast
7    Market Breakup by Product
    7.1    Urological
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Hormonal Therapy
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Gynecological
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Anti-infectives
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Others
        7.5.1 Market Trends
        7.5.2 Market Forecast
8    Market Breakup by Region
    8.1    North America
        8.1.1 United States
           8.1.1.1 Market Trends
           8.1.1.2 Market Forecast
        8.1.2 Canada
           8.1.2.1 Market Trends
           8.1.2.2 Market Forecast
    8.2    Asia-Pacific
        8.2.1 China
           8.2.1.1 Market Trends
           8.2.1.2 Market Forecast
        8.2.2 Japan
           8.2.2.1 Market Trends
           8.2.2.2 Market Forecast
        8.2.3 India
           8.2.3.1 Market Trends
           8.2.3.2 Market Forecast
        8.2.4 South Korea
           8.2.4.1 Market Trends
           8.2.4.2 Market Forecast
        8.2.5 Australia
           8.2.5.1 Market Trends
           8.2.5.2 Market Forecast
        8.2.6 Indonesia
           8.2.6.1 Market Trends
           8.2.6.2 Market Forecast
        8.2.7 Others
           8.2.7.1 Market Trends
           8.2.7.2 Market Forecast
    8.3    Europe
        8.3.1 Germany
           8.3.1.1 Market Trends
           8.3.1.2 Market Forecast
        8.3.2 France
           8.3.2.1 Market Trends
           8.3.2.2 Market Forecast
        8.3.3 United Kingdom
           8.3.3.1 Market Trends
           8.3.3.2 Market Forecast
        8.3.4 Italy
           8.3.4.1 Market Trends
           8.3.4.2 Market Forecast
        8.3.5 Spain
           8.3.5.1 Market Trends
           8.3.5.2 Market Forecast
        8.3.6 Russia
           8.3.6.1 Market Trends
           8.3.6.2 Market Forecast
        8.3.7 Others
           8.3.7.1 Market Trends
           8.3.7.2 Market Forecast
    8.4    Latin America
        8.4.1 Brazil
           8.4.1.1 Market Trends
           8.4.1.2 Market Forecast
        8.4.2 Mexico
           8.4.2.1 Market Trends
           8.4.2.2 Market Forecast
        8.4.3 Others
           8.4.3.1 Market Trends
           8.4.3.2 Market Forecast
    8.5    Middle East and Africa
        8.5.1 Market Trends
        8.5.2 Market Breakup by Country
        8.5.3 Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Allergan plc (AbbVie Inc.)
           13.3.1.1 Company Overview
           13.3.1.2 Product Portfolio
           13.3.1.3 SWOT Analysis
        13.3.2    Antares Pharma Inc.
           13.3.2.1 Company Overview
           13.3.2.2 Product Portfolio
           13.3.2.3 Financials
        13.3.3    AstraZeneca plc
           13.3.3.1 Company Overview
           13.3.3.2 Product Portfolio
           13.3.3.3 Financials
        13.3.4    Bayer AG
           13.3.4.1 Company Overview
           13.3.4.2 Product Portfolio
           13.3.4.3 Financials
           13.3.4.4 SWOT Analysis
        13.3.5    Bristol-Myers Squibb Company
           13.3.5.1 Company Overview
           13.3.5.2 Product Portfolio
           13.3.5.3 Financials
           13.3.5.4 SWOT Analysis
        13.3.6    Genentech Inc. (Roche Holding AG)
           13.3.6.1 Company Overview
           13.3.6.2 Product Portfolio
           13.3.6.3 SWOT Analysis
        13.3.7    GlaxoSmithKline plc
           13.3.7.1 Company Overview
           13.3.7.2 Product Portfolio
           13.3.7.3 Financials
           13.3.7.4 SWOT Analysis
        13.3.8    Merck & Co. Inc.
           13.3.8.1 Company Overview
           13.3.8.2 Product Portfolio
           13.3.8.3 Financials
           13.3.8.4 SWOT Analysis
        13.3.9    Novartis AG
           13.3.9.1 Company Overview
           13.3.9.2 Product Portfolio
           13.3.9.3 Financials
           13.3.9.4 SWOT Analysis
        13.3.10    Pfizer Inc.
           13.3.10.1 Company Overview
           13.3.10.2 Product Portfolio
           13.3.10.3 Financials
           13.3.10.4 SWOT Analysis
        13.3.11    Teva Pharmaceutical Industries Ltd.
           13.3.11.1 Company Overview
           13.3.11.2 Product Portfolio
           13.3.11.3 Financials

List of Figures

Figure 1: Global: Genitourinary Drugs Market: Major Drivers and Challenges
Figure 2: Global: Genitourinary Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Genitourinary Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 4: Global: Genitourinary Drugs Market: Breakup by Indication (in %), 2020
Figure 5: Global: Genitourinary Drugs Market: Breakup by Product (in %), 2020
Figure 6: Global: Genitourinary Drugs Market: Breakup by Region (in %), 2020
Figure 7: Global: Genitourinary Drugs (Prostate Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 8: Global: Genitourinary Drugs (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 9: Global: Genitourinary Drugs (Ovarian Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Genitourinary Drugs (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Genitourinary Drugs (Bladder Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Genitourinary Drugs (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Genitourinary Drugs (Cervical Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Genitourinary Drugs (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Genitourinary Drugs (Renal Cancer) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Genitourinary Drugs (Renal Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Genitourinary Drugs (Erectile Dysfunction) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Genitourinary Drugs (Erectile Dysfunction) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Genitourinary Drugs (Urinary Tract Infections) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Genitourinary Drugs (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Global: Genitourinary Drugs (Interstitial Cystitis) Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Global: Genitourinary Drugs (Interstitial Cystitis) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Global: Genitourinary Drugs (Hematuria) Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Global: Genitourinary Drugs (Hematuria) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 31: Global: Genitourinary Drugs (Urological) Market: Sales Value (in Million US$), 2015 & 2020
Figure 32: Global: Genitourinary Drugs (Urological) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 33: Global: Genitourinary Drugs (Hormonal Therapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 34: Global: Genitourinary Drugs (Hormonal Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 35: Global: Genitourinary Drugs (Gynecological) Market: Sales Value (in Million US$), 2015 & 2020
Figure 36: Global: Genitourinary Drugs (Gynecological) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 37: Global: Genitourinary Drugs (Anti-infectives) Market: Sales Value (in Million US$), 2015 & 2020
Figure 38: Global: Genitourinary Drugs (Anti-infectives) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 39: Global: Genitourinary Drugs (Other Products) Market: Sales Value (in Million US$), 2015 & 2020
Figure 40: Global: Genitourinary Drugs (Other Products) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 41: North America: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 42: North America: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 43: United States: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 44: United States: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 45: Canada: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 46: Canada: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 47: Asia-Pacific: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: Asia-Pacific: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: China: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: China: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: Japan: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: Japan: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: India: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: India: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: South Korea: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: South Korea: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: Australia: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: Australia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: Indonesia: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: Indonesia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Europe: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 64: Europe: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 65: Germany: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 66: Germany: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 67: France: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 68: France: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 69: United Kingdom: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 70: United Kingdom: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 71: Italy: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 72: Italy: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 73: Spain: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 74: Spain: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 75: Russia: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 76: Russia: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 77: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 78: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 79: Latin America: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 80: Latin America: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 81: Brazil: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 82: Brazil: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 83: Mexico: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 84: Mexico: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 85: Others: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 86: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 87: Middle East and Africa: Genitourinary Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 88: Middle East and Africa: Genitourinary Drugs Market: Breakup by Country (in %), 2020
Figure 89: Middle East and Africa: Genitourinary Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 90: Global: Genitourinary Drugs Industry: SWOT Analysis
Figure 91: Global: Genitourinary Drugs Industry: Value Chain Analysis
Figure 92: Global: Genitourinary Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Genitourinary Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Genitourinary Drugs Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 3: Global: Genitourinary Drugs Market Forecast: Breakup by Product (in Million US$), 2021-2026
Table 4: Global: Genitourinary Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 5: Global: Genitourinary Drugs Market: Competitive Structure
Table 6: Global: Genitourinary Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links